Advanced BioDesign Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$27.3M
- Investors
-
3
Advanced BioDesign General Information
Description
Developer of novel anticancer drugs is designed to focus specifically on targeting ALDH (aldehyde dehydrogenase) as a therapeutic approach. The company's lead compound, ABD-3001, selectively inhibits ALDH1 activity, disrupting cancer cell metabolism and triggering apoptosis while preserving healthy tissue and focuses on the discovery and production of recombinant molecules for myeloid leukemia, enabling institutions in the field of immunology to overcome tumor chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells.
Contact Information
Website
www.a-biodesign.comCorporate Office
- Parc Technologique de Lyon, Bâtiment D
- 655/575 Allée des Parcs
- 69800 Saint-Priest
- France
Corporate Office
- Parc Technologique de Lyon, Bâtiment D
- 655/575 Allée des Parcs
- 69800 Saint-Priest
- France
Advanced BioDesign Timeline
Advanced BioDesign Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 29-Dec-2023 | $27.3M | Completed | Clinical Trials - Phase 1 | ||
| 3. Grant | 15-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 28-Feb-2023 | $15.3M | $25.4M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC | 25-Feb-2020 | $10.1M | $10.1M | Completed | Clinical Trials - Phase 1 |
Advanced BioDesign Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| ADP D | ||||||||
| ADP D | ||||||||
| ADP D | ||||||||
| ADP B | ||||||||
| ADP B | ||||||||
| ADP B | 89,427 | $1.072258 | $15.01 | $15.01 | $15.01 | 24.23% | ||
| ADP B | 38,520 | $1.072258 | $10.72 | $10.72 | $10.72 | 10.44% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Advanced BioDesign Patents
Advanced BioDesign Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025229179-A1 | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer | Pending | 03-May-2024 | ||
| AU-2022212597-A1 | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent | Pending | 29-Jan-2021 | ||
| CA-3206551-A1 | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent | Pending | 29-Jan-2021 | ||
| EP-4035666-A1 | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent | Inactive | 29-Jan-2021 | ||
| EP-4284360-A1 | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent | Pending | 29-Jan-2021 | A61K31/5375 |
Advanced BioDesign Signals
Advanced BioDesign Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bpifrance | Sovereign Wealth Fund | |||
| Xerys Invest | PE/Buyout | Minority | ||
| Matwin | Accelerator/Incubator |
Advanced BioDesign FAQs
-
When was Advanced BioDesign founded?
Advanced BioDesign was founded in 2010.
-
Where is Advanced BioDesign headquartered?
Advanced BioDesign is headquartered in Saint-Priest, France.
-
What is the size of Advanced BioDesign?
Advanced BioDesign has 10 total employees.
-
What industry is Advanced BioDesign in?
Advanced BioDesign’s primary industry is Drug Discovery.
-
Is Advanced BioDesign a private or public company?
Advanced BioDesign is a Private company.
-
What is Advanced BioDesign’s current revenue?
The current revenue for Advanced BioDesign is .
-
How much funding has Advanced BioDesign raised over time?
Advanced BioDesign has raised $52.7M.
-
Who are Advanced BioDesign’s investors?
Bpifrance, Xerys Invest, and Matwin have invested in Advanced BioDesign.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process